ESPERITE (N.V) WITH CRYOSAVE ANNOUNCES THE RELEASE OF TWO CORD BLOOD STEM CELLS SAMPLES FOR TREATMENTS AND THEREFORE CONFIRMS THE IMPORTANCE OF STEM CELLS IN THE FIELD OF REGENERATIVE MEDICINE.
Amsterdam, The Netherlands – 2nd July 2019
read more
ESPERITE pioneers first treatment worldwide of Cerebral Palsy using two types of stem cells
CryoSave, part of ESPERITE, is the only private cord blood bank sponsoring a GCP clinical trial according to GMP-ATMP international guidelines
CryoSave leads and sponsors a multicentre clinical trial following GCP-ICH standards, for investigation of new treatment of Cerebral Palsy using dual infusion of two types of stem cells derived from umbilical cord blood and cord tissue processed by CryoSave
Geneva, Switzerland – 23 February 2015
Esperite (Euronext.: ESP), the European leader in stem cells cryopreservation now entering the fields of predictive medicine and translational regenerative medicine R&D, implements its own proprietary new technology for clinical grade production of autologous mesenchymal and stromal stem cells in its business unit The Cell Factory.
Zutphen, The Netherlands – 25 September 2014
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe announces that on December 10th 2013 a 4-year-old girl in Spain received an infusion of stem cells derived from her own umbilical cord blood for the treatment of her cerebral palsy. Cerebral palsy is one of the main areas of investigation of umbilical cord blood stem cell therapies.
Cryo-Save Group N.V. (Euronext: CRYO, “Cryo-Save”), Europe’s leading family stem cell bank, released a cord blood sample of a six-year-old girl from Portugal. The girl will be treated with her own umbilical cord blood stem cells at Duke University (USA) for cerebral palsy (CP). Cerebral palsy refers to a number of neurological disorders that appear in infancy or early childhood and permanently affects body movement and muscle coordination. It is a serious brain injury for which there is no standard cure available. The little girl received the first reinfusion of her own stem cells earlier this week.
Cryo-Save Group N.V. (Euronext: CRYO, “Cryo-Save”), Europe’s leading stem cell bank, today announces that another sample has been released. A six year old boy from Portugal went to Duke University (USA) to participate in a FDA approved clinical trial for cerebral palsy (CP). Cerebral palsy is a form of brain injury which causes physical disability and has no standard cure at the moment.
